Recent studies have aimed at a therapeutic approach for FTD–GRN to restore CNS PGRN levels [92] using adenovirus-associated virus-based gene therapy, SORT1-binding antibodies, and small molecules modulators (such as suberoylanilide hydroxamic acid, methyltransferase inhibitors, nor-binaltorphimine dihydrochloride, and dibutyryl-cAMP, sodium salt [93–96]. The gene discussed is GRN; the disease is frontotemporal dementia.